. 2023 Feb 17;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023

Table 2. Summary of Associations of Monoclonal Antibodies With Benefit and Harm Outcomes.

Intervention	Estimated absolute difference, per 1000 participants (95% CI)^a
	Benefit outcomes												Safety outcomes
	Rate of RSV infection		RSV-related hospitalization		Rate of ICU admission in all participants		Rate of supplemental oxygen use in all participants		Rate of MV use in all participants		Rate of wheezing		Drug-related AEs		All-cause mortality
Compared with placebo
Placebo, No. per 1000 participants	170	74		10		6		3		279		43		5
Nirsevimab	–123 (–138 to –100)^b	–54 (–64 to –38)^b		–10 (–10 to –2)^b^,^c		–59 (–65 to –40)^b		–3 (–3 to 9)^c^,^d		NA		–3 (–21 to 27)^e		–3 (–5 to 5)^e
Motavizumab	–136 (–146 to –125)^b	–48 (–58 to –33)^b		–8 (–9 to –4)^b		–59 (–63 to –54)^b		–3 (–3 to –1)^b		–12 (–52 to 33)^c^,^f		1 (–17 to 30)^e		–1 (–4 to 4)^e
Palivizumab	–108 (–127 to –82)^d	–39 (–48 to –28)^d		–5 (–7 to 0)^d		–55 (–61 to –42)^b		–1 (–2 to 1)^f		–111 (–172 to –27)^b^,^c		1 (–13 to 23)^e		–1 (–3 to 1)^e
Suptavumab	8 (–40 to 69)^g	0 (–34 to 59)^g		NA		NA		NA		NA		0 (–16 to 27)^f		2 (–5 to 139)^c^,^f
Motavizumab plus palivizumab	NA	NA		NA		NA		NA		NA		–10 (–28 to 31)^f		–1 (–5 to 45)^f
Compared with other intervention
Nirsevimab vs palivizumab	–14 (–34 to 2)^h	–15 (–25 to 4)^d		NA		–4 (–11 to 21)^d		NA		NA		–4 (–24 to 34)^e		–2 (–4 to 8)^e
Nirsevimab vs suptavumab	–131 (–151 to –98)^b	–54 (–66 to –27)^b		NA		NA		NA		NA		–3 (–24 to 40)^f		NA
Motavizumab vs nirsevimab	–15 (–27 to 6)^d	7 (–8 to 38)^d		NA		–1 (–7 to 18)^d		NA		NA		4 (–20 to 53)^e		2 (–1 to 29)^e
Motavizumab vs palivizumab	–29 (–41 to –8)^b	–9 (–17 to 3)^d		–3 (–4 to 0)^b		–5 (–8 to 1)^d		–2 (–2 to 0)^b		NA		0 (–13 to 17)^e		0 (–2 to 5)^e
Motavizumab vs suptavumab	–145 (–157 to –127)^b	–48 (–62 to –18)^b		NA		NA		NA		NA		0 (–22 to 45)^f		NAⁱ
Palivizumab vs suptavumab	–117 (–140 to –79)^b	–39 (–57 to –6)^b		NA		NA		NA		NA		1 (–20 to 38)^f		NAⁱ
Motavizumab plus palivizumab vs nirsevimab	NA	NA		NA		NA		NA		NA		–7 (–28 to 48)^f		3 (–2 to 99)^f
Motavizumab plus palivizumab vs motavizumab	NA	NA		NA		NA		NA		NA		–10 (–26 to 17)ⁱ		0 (–4 to 44)ⁱ
Motavizumab plus palivizumab vs palivizumab	NA	NA		NA		NA		NA		NA		–11 (–28 to 22)ⁱ		0 (–4 to 49)ⁱ
Motavizumab plus palivizumab vs suptavumab	NA	NA		NA		NA		NA		NA		–10 (–30 to 41)ⁱ		NA

Abbreviations: AEs, adverse events; ICU, intensive care unit; MV, mechanical ventilation; NA not applicable; RSV, respiratory syncytial virus.

^{^a}

Compared with standard care. For the rates of ICU admission, supplemental oxygen use, and MV use, the included studies stated these analyses were done in all participants.

^{^b}

Better than placebo and some other interventions, with high or moderate certainty.

^{^c}

Obtained from direct evidence.

^{^d}

Better than placebo but no better than any other interventions, with high or moderate certainty.

^{^e}

No more harmful than placebo, with high or moderate certainty.

^{^f}

May be better than placebo and some alternatives or may be no more harmful than placebo, with low or very low certainty.

^{^g}

May be no better than placebo or may be more harmful than placebo and some alternatives, with low or very low certainty.

^{^h}

May be better than placebo but no better than other interventions or may be more harmful than placebo but no worse than other interventions, with low or very low certainty.

^ⁱ

No better than placebo, with high or moderate certainty.